BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
71.44
-1.39 (-1.91%)
At close: Mar 28, 2025, 4:00 PM
69.00
-2.44 (-3.42%)
Pre-market: Mar 31, 2025, 8:43 AM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 94, with a low estimate of 65 and a high estimate of 126. The average target predicts an increase of 31.58% from the current stock price of 71.44.
Analyst Consensus: Buy
* Price targets were last updated on Feb 24, 2025.
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 10 | 10 | 10 | 10 | 11 | 11 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 21 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $98 | Hold → Buy | Upgrades | $98 | +37.18% | Feb 24, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $78 → $80 | Hold | Maintains | $78 → $80 | +11.98% | Feb 20, 2025 |
| Citigroup | Citigroup | Hold Maintains $81 → $82 | Hold | Maintains | $81 → $82 | +14.78% | Feb 20, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $70 | Hold | Reiterates | $70 | -2.02% | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $90 | Buy | Reiterates | $90 | +25.98% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
3.20B
from 2.85B
Increased by 12.23%
Revenue Next Year
3.52B
from 3.20B
Increased by 9.90%
EPS This Year
3.20
from 2.21
Increased by 45.02%
EPS Next Year
4.02
from 3.20
Increased by 25.73%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.2B | ||
| Avg | 3.2B | 3.5B | 3.8B | ||
| Low | 3.0B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.6% | 21.7% | 19.9% | ||
| Avg | 12.2% | 9.9% | 8.4% | ||
| Low | 4.6% | -2.9% | -8.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.78 | 5.17 | 6.87 | ||
| Avg | 3.20 | 4.02 | 5.10 | ||
| Low | 2.20 | 1.08 | 3.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.3% | 61.4% | 70.6% | ||
| Avg | 45.0% | 25.7% | 26.7% | ||
| Low | -0.5% | -66.3% | -12.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.